Press Releases and News

Aphios Spins Off Amylon LLC To Develop Novel Alzheimer's Disease Drug
November 20, 2013
Woburn, Mass. – Aphios Corporation announces today that it has spun-off a subsidiary Amylon™ LLC to finance, develop and commercialize APH-1104 for mild to moderate Alzheimer's disease (AD) and other CNS disorders [Patents Pending].

"There are three enzymes that appear to be directly involved in the pathophysiology of AD. Current AD research is centered on inhibiting beta (β)-secretase and gamma (γ)-secretase to decrease beta amyloid (Aβ) and the assembly of tau tangles, biochemical 'signatures' of AD which are the basis of cognitive decline. To date, all the recent clinical trials to downregulate or inhibit β-secretase or γ-secretase have failed," comments Trevor P. Castor, President & CEO. Dr. Castor continues, "Our strategy is to up-regulate the third enzyme, alpha (α)-secretase, to eliminate the substrate for Aβ, thereby preventing and reducing plaques and tau entanglement."

According to Dr. J. Steven Alexander, a collaborator at Louisiana State University Health Sciences Center, Shreveport, LA (LSUHSC), APH-1104 is a highly effective α-secretase modulator several orders of magnitude more potent than typical modulators. "In dose- and time-dependent studies, APH-1104 showed a very high level of effectiveness in α-secretase assays. An even more impressive finding is that an oral formulation of a less potent analog rapidly reversed cognitive deficits in triple transgenic animal models of AD."

In 2010, Aphios received a 3-year, NIH Fast Track SBIR grant to develop an oral formulation of APH-0703. This research has led to the discovery of a more potent analog, APH-1104, which Amylon LLC plans to develop for Alzheimer's disease.


Amylon™ LLC, a limited liability Delaware corporation, mission is to develop and commercialize, APH-1104, for mild to moderate Alzheimer's disease and other CNS disorders such as Down's syndrome and glaucoma. Amylon is currently raising debt/equity capital from high net worth investors and institutional investors. Potential investors are encouraged to learn more about Amylon and its plans at


Aphios® Corporation, a Delaware C-corporation, is a clinical-stage biotechnology company, which is developing enabling technology platforms and enhanced therapeutics for chronic, debilitating diseases, and improving the quality of life of cancer and Alzheimer's disease patients.

The research described is supported by Grant Number 5R44AG034760 from the National Institute on Aging (NIA), NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIA or NIH.